Jijun Dong

Jijun Dong's work experience includes roles at various biotechnology and pharmaceutical companies. Jijun is currently serving as the Chief Scientific Officer at Salubris Biotherapeutics since May 2023. Previously, from 2022 to 2023, they worked as the Vice President Biologics at Xilio Therapeutics, Inc. Prior to that, they were the Executive Director at Cygnal Therapeutics from 2021 to 2022. From 2017 to 2021, they held positions at Alkermes, first as a Sr. Director and then as a Principal Scientist. Jijun led cross-functional project teams and played a key role in the development of targeted immunotherapies for cancer treatment. Before Alkermes, Jijun Dong worked at Novartis as an Investigator II from 2013 to 2017 and as an Investigator I from 2010 to 2013. Their responsibilities at Novartis involved developing and characterizing therapeutic antibodies and proteins for cardiovascular and metabolic diseases, as well as identifying and characterizing targets for blood brain-barrier penetration. Jijun also has experience as a Postdoctoral Fellow at the Whitehead Institute from 2006 to 2010 and as a research assistant at Emory University from 2000 to 2006. Jijun Dong began their career as a Chemist and research assistant at Peking University from 1998 to 2000.

Jijun Dong completed their education with a Ph.D. in biochemistry from Emory University, where they studied from 2000 to 2006. Prior to that, they earned a Bachelor of Science degree in chemistry from Peking University, which they attended from 1996 to 2000.